The publisher / what this is
About CJC-1295 Direct
An independent editorial reading of the CJC-1295 literature — calm, cited, and clear about what it is and what it is not.
What CJC-1295 Direct is
CJC-1295 Direct is an independent editorial project that publishes summaries of the peer-reviewed research literature on CJC-1295. We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science — a calm, after-hours reading of a small and specific body of research.
The compound's literature is genuinely thin: a handful of mid-2000s Phase-1 pharmacokinetic papers, one rat bioconjugate study, one knockout-mouse growth paper, a proteomics note. We read it at that scale on purpose. Rather than padding a dashboard with manufactured density, we let a few well-chosen findings breathe and we mark the gaps — no large efficacy trials, no long-term safety data — as findings in their own right.
On the word 'Direct'
The word 'Direct' in this site's name is editorial framing, not a claim about services. It describes how we read the literature — straight, plainly, without embellishment, and without the hedging that buries findings in qualifications. It does not mean direct supply, direct sale, or direct access to any product or prescriber. There is no checkout here, no order form, no dispensing, and no clinic behind this page.
We keep one distinction at the center of everything: CJC-1295 DAC, the albumin-bound multi-day form, versus the short-acting no-DAC Modified GRF 1-29. The marketing world constantly blurs the two; the studies do not, and neither do we. Holding that line is most of what an honest digest of this compound has to do.
How we cite
Every quantitative claim on this site maps to a numbered citation in the study references list, with a DOI or PubMed link so any reader can check it at the source. When the evidence is precise — the 5.8-8.1 day half-life [1], the 4-fold rat GH response [6] — we state it precisely. When it is absent, we say so rather than implying more than the record holds.
We write in third person, attributed to the studies, and we do not recommend doses for humans. CJC-1295 is not approved for human use anywhere [1]; what we describe is what was administered to which species, at which dose, by which route, in published research. That is the whole remit of this site, and we keep to it.